shutterstock_1661915599_med.jpg

CONTACT INFORMATION FOR INVESTORS

Teresa Whalen, RPh   |   CEO   |    twhalen@cytoagents.com   |   412-303-1200

PHASE 2 STAGE IMMUNOTHERAPY: RAISING $25M SERIES A

TARGETING HIGH UNMET NEEDS

INFECTIOUS AND NON-INFECTIOUS INDICATIONS

• CAR-T Cell Therapy

• COVID-19

• Vaping Induced Lung Injury

• Influenza

• Traumatic Brain Injury

• Juvenile Idiopathic Arthritis

SERIES A USE OF PROCEEDS

$25M SERIES A: USE OF PROCEEDS

• CAR-T CRS Non Clinical Studies

• CAR-T CRS Clinical Phase 2A

• Phase 2 COVID-19 Trial

• Non Human Primate COVID-19 Studies

• ARDS/Vaping Non Clinical Studies

• Expand Manufacturing Capabilities

• Expand Patent Portfolio

• Expand Strategic Partnerships

INVESTABLE ASSET

• New Chemical Entity to US and Europe

• Established Safety Profile

• Phase 1 Human Clinical Trial Complete 2/2021

• Awarded $3.6M NIH Non-Dilutive Grants

Cost Effective, Shelf Stable, Broadly Accessible Treatment

• Can be Used as Treatment and Prophylaxis

• Acute and Non-Acute Indications

• Efficacy Regardless of Viral Strain: Ideal Stockpiling Candidate

• Manufacturing Partnership Established

• Strategic Partner CDA Signed to Accelerate FDA Pathway

© 2021 by CytoAgents

  • LI-In-Bug